It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Real-world data on the effectiveness of neutralizing casirivimab-imdevimab monoclonal antibody (Cas-Imd mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients may inform the response to future SARS-CoV-2 variants.
Methods
This study covers an observational retrospective data analysis in Banner Health Care System sites, mainly in Arizona. During the study period, the prevalence of SARS-CoV-2 Delta variant was between 95% and 100%. Of 29 635 patients who tested positive for coronavirus disease 2019 (COVID-19) between 1 August 2021 and 30 October 2021, in the Banner Health Care System, the study cohort was split into 4213 adult patients who received Cas-Imd mAb (1200 mg) treatment compared to a PS-matched 4213 untreated patients. The primary outcomes were the incidence of all-cause hospitalization, intensive care unit (ICU) admission, and mortality within 30 days of Cas-Imd mAb administration or Delta variant infection.
Results
Compared to the PS-matched untreated cohort, the Cas-Imd mAb cohort had significantly lower all-cause hospitalization (4.2% vs 17.6%; difference in percentages, −13.4 [95% confidence interval {CI}, −14.7 to −12.0]; P < .001), ICU admission (0.3% vs 2.8%; difference, −2.4 [95% CI, −3.0 to −1.9]; P < .001), and mortality (0.2% vs 2.0%; difference, −1.8 [95% CI, −2.3 to −1.3]; P < .001) within 30 days. The Cas-Imd mAb treatment was associated with lower rate of hospitalization (hazard ratio [HR], 0.22 [95% CI, .19–.26]; P < .001) and mortality (HR, 0.11 [95% CI, .06–.21]; P < .001).
Conclusions
Cas-Imd mAb treatment was associated with a lower hospitalization rate, ICU admission, and mortality within 30 days among patients infected with the SARS-CoV-2 Delta variant.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Division of Infectious Disease, College of Medicine, University of Arizona , Tucson, Arizona , USA
2 Division of Nephrology, Banner University Medical Center , Tucson, Arizona , USA
3 Department of Epidemiology and Biostatistics, College of Public Health, University of Arizona , Tucson, Arizona , USA
4 Division of Clinical Pharmacy, Banner University Medical Center , Tucson, Arizona , USA
5 Department of Surgery, Banner University Medical Center , Tucson, Arizona , USA
6 Department of Medicine, Banner University Medical Center Phoenix , Phoenix, Arizona , USA
7 Division of Clinical Data Analytics and Decision Support, Department of Medicine, College of Medicine–Phoenix, University of Arizona , Phoenix, Arizona , USA
8 Division of Nephrology, College of Medicine, University of Arizona , Tucson, Arizona , USA
9 Information Systems, Naveen Jindal School of Management, University of Texas at Dallas , Dallas, Texas , USA
10 Medical University of South Carolina , Lancaster, South Carolina , USA